Bill

Bill > SB665


NH SB665

NH SB665
Relative to pharmacy benefits managers, managed care laws, notice of drug pricing optionsand pharmacy benefit manager business practices.


summary

Introduced
02/04/2026
In Committee
05/01/2026
Crossed Over
03/27/2026
Passed
Dead
05/14/2026

Introduced Session

2026 Regular Session

Bill Summary

This bill: I. Requires written agreement to be formed between pharmacy benefits managers and health carriers before benefits managers can operate. II. Amends pharmacy benefits manager reporting and examination requirements. III. Raises the value of the maximum administrative fine that can be levied for violations of the state's pharmacy benefits manger laws. IV. Requires pharmacies to make efforts to notify consumers of their right to request the lowest available price for prescription drugs. V. Prohibiting health carriers or pharmacy benefit managers from penalizing, requiring, or providing, financial incentives to covered persons as incentives to use specific retail, mail order pharmacy, or another network pharmacy provider that is an affiliate of the pharmacy benefit manager.

AI Summary

This bill aims to increase transparency and fairness in prescription drug pricing by requiring pharmacies to inform consumers of their right to request the lowest available price for their medications and to provide information on various pricing options, including cash prices and discounts. It also mandates that pharmacy benefit managers (PBMs), which manage prescription drug benefits for health carriers, must have written agreements with health carriers outlining their duties and fiduciary responsibilities, and are subject to increased oversight and higher administrative fines for violations, with the maximum fine for violations of state PBM laws being raised to $10,000 per day. Furthermore, the bill prohibits health carriers or PBMs from steering patients towards affiliated pharmacies through financial incentives or penalties, and requires PBMs to report detailed financial information about rebates and fees collected from pharmaceutical manufacturers to the state. The bill also extends the timeframe for notifying consumers about changes to drug formularies and increases the font size for such notices, and clarifies that denials of exception requests for medically necessary drugs are considered adverse determinations.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (17)

Last Action

Inexpedient to Legislate: Motion Adopted Voice Vote 05/14/2026 House Journal 13 (on 05/14/2026)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...